How to Handle Disputes in Regulatory Audit Observations

Introduction: When and Why Audit Observations Are Disputed

In the conduct of clinical trials, regulatory inspections are a critical mechanism for ensuring compliance with Good Clinical Practice (GCP). However, there may be instances where sponsors, CROs, or investigator sites disagree with one or more findings reported during an inspection. Disputing an audit observation must be approached with caution, professionalism, and an evidence-based response framework.

This article outlines when it’s appropriate to challenge an audit finding, how to structure your response, and the processes available through regulatory bodies such as the FDA, EMA, and MHRA.

Understanding the Nature of Disputable Observations

Not all audit findings are equally subject to dispute. Situations that may warrant a challenge include:

• Findings based on outdated SOPs or regulatory references
• Observations that result from misinterpretation of study-specific procedures
• Discrepancies in source documentation that were already corrected before the audit
• Generalized statements not supported by evidence

It is critical to distinguish between a valid regulatory deficiency and a subjective interpretation. The goal should be to clarify—not antagonize—the inspection authority.

Initial Steps: Internal Review and Stakeholder Alignment

Before submitting a formal disagreement, perform an internal assessment:

1. Gather all documents referenced in the observation
2. Review internal monitoring reports, site visit logs, and previous correspondence
3. Convene a multidisciplinary meeting involving QA, regulatory, clinical, and legal teams
4. Assess if clarification or correction was already underway before the audit

Ensure the sponsor and any CRO partners are aligned in the position and tone of the dispute response.

How to Formally Dispute an Audit Observation

Agencies provide mechanisms for responding to audit findings. For instance:

• FDA: Response to a Form 483 may include disagreement with certain observations, explained in a respectful, evidence-backed cover letter. A follow-up meeting with the FDA may be requested.
• EMA: The inspector may be contacted post-inspection for clarification before a formal response is submitted.
• MHRA: Allows queries or challenges to inspection classification results via written communication within a defined timeframe.

Structure of a Dispute Response

A typical dispute or clarification letter should include:

Case Study: Misinterpreted SAE Reporting Process

Scenario: A sponsor received a Form 483 stating “Delayed SAE reporting to the sponsor by more than 24 hours.”

Internal Review: The event was logged in the EDC system, but the monitor’s notification was delayed by system outage. SOP required logging, not separate email to sponsor.

Action: The sponsor submitted a clarification with EDC timestamps and SOP excerpt, requesting removal of the observation.

Outcome: FDA acknowledged the explanation, and the final Establishment Inspection Report (EIR) did not include the finding.

Risks of Disputing Without Sufficient Basis

While it is important to defend the integrity of your processes, disputing findings without adequate documentation can backfire. Risks include:

• Damaging the sponsor’s reputation for transparency
• Delays in approval or regulatory clearance
• Increased scrutiny in future inspections
• Loss of credibility with inspectors

Best Practices for Managing Disputed Observations

• Remain professional and factual—avoid emotional or defensive language
• Back every argument with verifiable documentation
• If in doubt, request clarification before filing a formal dispute
• Track all correspondence with the regulatory body
• Engage legal or regulatory consultants for high-stakes inspections

Conclusion: Disputes Must Strengthen, Not Undermine Compliance

Challenging an audit observation is not a confrontation—it is an opportunity to ensure accuracy and fairness in the regulatory record. When handled strategically, a well-documented dispute can reinforce an organization’s commitment to quality, compliance, and transparency. Always assess the risk, communicate clearly, and document thoroughly.